Ebopiprant is a Small Molecule owned by Organon, and is involved in 4 clinical trials, of which 2 were completed, 1 is ongoing, and 1 is planned.

OBE-022 acts by antagonizing Prostaglandin F2 alpha (PGF2a) receptors. The receptor belongs to the G-protein coupled receptor family. Activation and stimulation of myometrium leads to increased uterine contractility. The drug candidate by blocking PGF2a receptors provides tocolytic effect for women in preterm labour to postpone the premature birth.

The revenue for Ebopiprant is expected to reach a total of $236m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Ebopiprant NPV Report.

Ebopiprant was originated by Merck and is currently owned by Organon. ObsEva is the other company associated in development or marketing of Ebopiprant.

Ebopiprant Overview

Ebopiprant (OBE-022) is under development for the treatment of premature labor (tocolysis). The drug candidate is administered orally. It is a small molecule inhibitor of prostaglandin F2 alpha (PGF2alpha) receptor. It is a new chemical entity (NCE). It was also under development for severe dysmenorrhea.

ObsEva Overview

ObsEva is a clinical-stage biopharmaceutical company that develops and commercializes drugs for women’s reproductive health and pregnancy. The company’s product portfolio comprises pipeline products for controlling preterm labor by reducing inflammation, decreasing uterine contractions, and preventing cervical changes and membrane ruptures; for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women and to decrease contractions, improve uterine blood flow and enhance the receptivity of the endometrium to embryo implantation. ObsEva is headquartered in Geneva, Switzerland.

The company reported revenues of (US Dollars) US$20.1 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$54.5 million in FY2021, compared to an operating loss of US$79.7 million in FY2020. The net loss of the company was US$58.4 million in FY2021, compared to a net loss of US$83 million in FY2020. The company reported revenues of US$3.7 million for the third quarter ended September 2022, an increase of 42.1% over the previous quarter.

Quick View – Ebopiprant

Report Segments
  • Innovator
Drug Name
  • Ebopiprant
Administration Pathway
  • Oral
Therapeutic Areas
  • Women’s Health
Key Companies
  • Sponsor Company: Organon
  • Originator: Merck
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.